Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
-
Trump 'happy' to work with Democrats on health care, if shutdown ends
-
Trump says may invoke Insurrection Act to deploy more troops in US
-
UNESCO board backs Egyptian for chief after US row
-
Greta Thunberg lands in Greece with expelled Gaza flotilla activists
-
Unreachable Nobel winner hiking 'off the grid'
-
Retirement or marketing gimmick? Cryptic LeBron video sets Internet buzzing
-
CAF 'absolutely confident' AFCON will go ahead in protest-hit Morocco
-
Paris stocks slide amid French political upheaval, Tokyo soars
-
EU should scrap ban on new combustion-engine sales: Merz
-
US government shutdown enters second week, no end in sight
-
World MotoGP champion Marquez to miss two races with fracture
-
Matthieu Blazy reaches for the stars in Chanel debut
-
Macron gives outgoing French PM final chance to salvage government
-
Illinois sues to block National Guard deployment in Chicago
-
Exiled Willis succeeds Dupont as Top 14 player of the season
-
Hamas and Israel open talks in Egypt under Trump's Gaza peace plan
-
Mbappe undergoing treatment for 'small niggle' at France camp: Deschamps
-
Common inhalers carry heavy climate cost, study finds
-
Madagascar president taps general for PM in bid to defuse protests
-
Greta Thunberg lands in Greece among expelled Gaza flotilla activists
-
UEFA 'reluctantly' approves European league games in US, Australia
-
Hundreds protest in Madagascar as president to announce new premier
-
Greta Thunberg lands in Greece among Gaza flotilla activists deported from Israel
-
UNESCO board backs Egyptian ex-minister for top job: official
-
Facing confidence vote, EU chief calls for unity
-
Cash-strapped UNHCR shed 5,000 jobs this year
-
Mbappe to have 'small niggle' examined at France camp: Deschamps
-
Brazil's Lula asks Trump to remove tariffs in 'friendly' phone call
-
Paris stocks slide as French PM resigns, Tokyo soars
-
'Terrible' Zverev dumped out of Shanghai by France's Rinderknech
-
What are regulatory T-cells? Nobel-winning science explained
-
Indirect talks on ending Gaza war begin in Sharm El-Sheikh: Egypt media
-
OpenAI signs multi-billion dollar chip deal with AMD
-
Salah under fire as Liverpool star loses his spark
-
Paris stocks drop as French PM resigns, Tokyo soars
-
ICC finds Sudan militia chief guilty of crimes against humanity
-
Zverev dumped out of Shanghai Masters by France's Rinderknech
-
One hiker dead, hundreds rescued after heavy snowfall in China
-
Hundreds stage fresh anti-government protests in Madagascar
-
Feminist icon Gisele Pelicot back in court as man appeals rape conviction
-
US government shutdown enters second week
-
Kasatkina ends WTA season early after hitting 'breaking point'
-
Paris stocks drop as French PM resigns
-
Death toll from Indonesia school collapse rises to 63
-
Medicine Nobel to trio who identified immune system's 'security guards'
-
UN rights council launches probe into violations in Afghanistan
-
UK author Jilly Cooper dies aged 88
-
Jilly Cooper: Britain's queen of the 'bonkbuster' novel
-
Streaming stars' Le Mans race scores Twitch viewer record
-
England rugby star Moody 'shocked' by motor neurone disease diagnosis
NYSE - LSE
Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Half Year 2025 Financial Results and Business Update Call on Friday, August 29, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.
Event: Altamira Therapeutics First Half 2025 Financial Results and Business Update Call
Date: Friday, August 29, 2025
Time: 8:00 am ET
Access:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 427043
Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/52765
Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.
The call will be in listen-only mode.
A replay of the call will be available 30 minutes after the live event via the Investors section of the Altamira website at https://ir.altamiratherapeutics.com/.
Replay access:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 52765
Expiration: Friday, September 12, 2025
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
Investor Contact
SOURCE: Altamira Therapeutics
View the original press release on ACCESS Newswire
Y.Aukaiv--AMWN